Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,743.20
(
0.09%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.11
(
-0.31%
)
Bitcoin
71,245.00
(
1.93%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 40501

Wednesday, 01/10/2007 7:16:25 PM

Wednesday, January 10, 2007 7:16:25 PM

Post# of 257262
Lucentis (55% penetration of new AMD patients) and off-label Avastin had close to 100% penetration of the U.S. wet AMD market between them during 4Q06. In other words, almost everyone in the U.S. with diagnosed clinically-relevant AMD is getting treatment, and Macugen and Visudyne have already become non-factors. (Source: Today’s DNA CC)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now